Zoya Gluzman
No más puestos en curso
Historial de carrera de Zoya Gluzman
Antiguos cargos conocidos de Zoya Gluzman.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
VESSL Therapeutics Ltd.
 VESSL Therapeutics Ltd. Medical SpecialtiesHealth Technology VESSL Therapeutics Ltd. develops cell-based therapies for large patient populations. Its solutions include MultiGeneAngio fo Peripheral Artery Disease and MultiGeneGraft for end-stage renal disease. The company was founded in August 2000 by Moshe Y. Flugelman and Basil S. Lewis and is headquartered in Haifa, Israel. | Corporate Officer/Principal | - | - |
GeneGrafts Ltd.
 GeneGrafts Ltd. BiotechnologyHealth Technology GeneGrafts Ltd. develops proprietary technology for modulating excitable tissues. Its technology is used for the treatment of cardiac arrhythmias, Parkinson's disease and other neurological disorders. The company was founded by Yair Feld, Lior Gepstein, Shimon Marom and Meira Melamed Frank in 2003 and is headquartered in Haifa, Israel. | Director Técnico/Científico/I+D | 01/01/2005 | - |
Formación de Zoya Gluzman.
| Technion-Israel Institute of Technology | Doctorate Degree |
Estadísticas
Internacional
| Israel | 4 |
Operativa
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
| Masters Business Admin | 1 |
Sectorial
| Health Technology | 3 |
| Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas privadas | 2 |
|---|---|
GeneGrafts Ltd.
GeneGrafts Ltd. BiotechnologyHealth Technology GeneGrafts Ltd. develops proprietary technology for modulating excitable tissues. Its technology is used for the treatment of cardiac arrhythmias, Parkinson's disease and other neurological disorders. The company was founded by Yair Feld, Lior Gepstein, Shimon Marom and Meira Melamed Frank in 2003 and is headquartered in Haifa, Israel. | Health Technology |
VESSL Therapeutics Ltd.
VESSL Therapeutics Ltd. Medical SpecialtiesHealth Technology VESSL Therapeutics Ltd. develops cell-based therapies for large patient populations. Its solutions include MultiGeneAngio fo Peripheral Artery Disease and MultiGeneGraft for end-stage renal disease. The company was founded in August 2000 by Moshe Y. Flugelman and Basil S. Lewis and is headquartered in Haifa, Israel. | Health Technology |
- Bolsa de valores
- Insiders
- Zoya Gluzman
- Experiencia
